Literature DB >> 6995732

Multiple myeloma: current concepts in diagnosis and management.

J M Paredes, B S Mitchell.   

Abstract

The basic pathologic process in multiple myeloma is the neoplastic proliferation of a single clone of plasma cells. Although the events which trigger autonomous cell growth are not well understood, the secretion of an M component, a serum or urinary immunoglobulin molecule or a light chain fragment by the vast majority of myeloma cells has provided a biologic marker which has greatly facilitated the study of this disease Some of the more recent clinical concepts which have evolved from studies on the plasma cell and the immunoglobulin molecule are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995732     DOI: 10.1016/s0025-7125(16)31590-5

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

1.  Immunoelectrophoretic investigations in 55 patients with systemic amyloidosis.

Authors:  D Vital Durand; J L Touraine; R Levrat; P Zech; J Traeger; E Lejeune; R Creyssel
Journal:  Blut       Date:  1984-08

2.  Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.

Authors:  B Steinke; F W Busch; C Becherer; P Ostendorf; H D Waller
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Authors:  K Shimizu; O Kamiya; N Hamajima; H Mizuno; M Kobayashi; N Hirabayashi; H Takeyama; R Kato; K Kawashima; M Nitta
Journal:  Jpn J Cancer Res       Date:  1990-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.